Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
McKinsey
Dow
Healthtrust
Chubb
Farmers Insurance
Express Scripts
US Army

Generated: December 17, 2018

DrugPatentWatch Database Preview

SYMPROIC Drug Profile

« Back to Dashboard

When do Symproic patents expire, and what generic alternatives are available?

Symproic is a drug marketed by Shionogi Inc and is included in one NDA. There are three patents protecting this drug.

This drug has fifty patent family members in eighteen countries.

The generic ingredient in SYMPROIC is naldemedine tosylate. Two suppliers are listed for this compound. Additional details are available on the naldemedine tosylate profile page.

Summary for SYMPROIC
International Patents:50
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 1
Drug Prices: Drug price information for SYMPROIC
DailyMed Link:SYMPROIC at DailyMed
Drug patent expirations by year for SYMPROIC
Generic Entry Opportunity Date for SYMPROIC
Generic Entry Date for SYMPROIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for SYMPROIC
Drug ClassOpioid Antagonist
Mechanism of ActionOpioid Antagonists
Synonyms for SYMPROIC
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide
03KSI6WLXH
1345728-04-2
17-(Cyclopropylmethyl)-6,7-didehydro-4,5a-epoxy-3,6,14-trihydroxy-N-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide 4-methylbenzenesulfonic acid
17-(cyclopropylmethyl)-6,7-didehydro-4,5alpha-epoxy-3,6,14-trihydroxy-N-(2-(3-phenyl- 1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide
916072-89-4
AKOS032945757
CHEMBL2105755
CHEMBL3039508
D0Q2HO
D0Q3PD
D10188
D10478
DB11691
DTXSID10158809
GTPL9150
Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14- trihydroxy-N-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5alpha)-
Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14-trihydroxy-N-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5alpha)-, 4-methylbenzenesulfonate (1:1)
NALDEMEDINE
Naldemedine (USAN/INN)
Naldemedine [USAN:INN]
naldemedine tosilate
Naldemedine tosylate
Naldemedine tosylate (JAN/USAN)
Naldemedine tosylate [USAN]
nalmedine
S 297995
S-297,995
S-297995
SCHEMBL9880572
UNII-03KSI6WLXH
UNII-V1N8F1RVVO
V1N8F1RVVO

US Patents and Regulatory Information for SYMPROIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shionogi Inc SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Shionogi Inc SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Shionogi Inc SYMPROIC naldemedine tosylate TABLET;ORAL 208854-001 Mar 23, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
McKinsey
Dow
Healthtrust
Chubb
Farmers Insurance
Express Scripts
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.